|
|
|
 |
|
 |
Partners
Kamada’s philosophy embraces the joining of forces with industry partners. As each partner brings unique strengths and abilities into the partnership, a greater whole is created. Kamada is looking to complement the partners’ knowledge, skills and resources with its own proprietary technology, production capabilities and extensive experience.
As for Q1/2008, Kamada’s strategic alliances include agreements with several partners, with a focus on product development, technology and distribution rights, as well as on the supply of raw materials.
The company’s partnerships include:
 |
Joint ventures with international companies for the development and production of AAT from their own secured source of fraction IV paste |
|
Development of an aerosolized AAT treatment through collaboration with PARI, a German leader in inhalation devices |
|
Long term supply agreements (paste and/or plasma) |
Partnering possibilities
Among possible collaborations, the following are particularly exciting, involving Kamada’s most innovative products:
|
Strategic collaborations to market and distribute AAT in Europe and the USA: AAT (RespiraTM) treats Congenital Emphysema, an inborn deficiency of Alpha-1 Proteinase inhibitor. Kamada develops AAT treatment for the administration by infusion as well as for the administration by inhalation. The inhalation-administered AAT, currently under development, may potentially treat additional respiratory diseases. |
|
Strategic collaborations to develop new indications and applications for Transferrin: As Kamada is a world-leading Transferrin manufacturer and IP holder, developers of anti-cancer, Transferrin-conjugated drugs can find in us a natural strategic partner and supplier. In particular, the company has established experience in the production of Human Transferrin for diagnostic/in vitro uses. |
|
Global partnerships/distributorships in various territories to bring Kamada’s unique products to new markets |
|
Collaborations for new product development |
|
|
|
|
|
More
|
|
